AU2021327861A1 - Modified il-18 polypeptides and uses thereof - Google Patents

Modified il-18 polypeptides and uses thereof Download PDF

Info

Publication number
AU2021327861A1
AU2021327861A1 AU2021327861A AU2021327861A AU2021327861A1 AU 2021327861 A1 AU2021327861 A1 AU 2021327861A1 AU 2021327861 A AU2021327861 A AU 2021327861A AU 2021327861 A AU2021327861 A AU 2021327861A AU 2021327861 A1 AU2021327861 A1 AU 2021327861A1
Authority
AU
Australia
Prior art keywords
modified
polypeptide
residue
seq
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021327861A
Other languages
English (en)
Other versions
AU2021327861A9 (en
Inventor
Matilde ARÉVALO-RUIZ
Jeffrey William BODE
Régis BOEHRINGER
Jean-philippe CARRALOT
Camille DELON
Claudia FETZ
Alexander Flohr
Anna HAYDN
Benoit Hornsperger
Roberto Iacone
Bertolt Kreft
Vijaya Raghavan PATTABIRAMAN
Chongqing Wang
Amelie WIEDERKEHR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bright Peak Therapeutics AG
Original Assignee
Bright Peak Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bright Peak Therapeutics AG filed Critical Bright Peak Therapeutics AG
Publication of AU2021327861A1 publication Critical patent/AU2021327861A1/en
Publication of AU2021327861A9 publication Critical patent/AU2021327861A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2021327861A 2020-08-19 2021-08-19 Modified il-18 polypeptides and uses thereof Pending AU2021327861A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067658P 2020-08-19 2020-08-19
US63/067,658 2020-08-19
PCT/IB2021/000574 WO2022038417A2 (en) 2020-08-19 2021-08-19 Modified il-18 polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
AU2021327861A1 true AU2021327861A1 (en) 2023-05-04
AU2021327861A9 AU2021327861A9 (en) 2023-07-06

Family

ID=78032459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021327861A Pending AU2021327861A1 (en) 2020-08-19 2021-08-19 Modified il-18 polypeptides and uses thereof

Country Status (9)

Country Link
US (1) US20220056091A1 (https=)
EP (1) EP4200323A2 (https=)
JP (1) JP2023538422A (https=)
KR (1) KR20230052956A (https=)
CN (1) CN116368148A (https=)
AU (1) AU2021327861A1 (https=)
CA (1) CA3189327A1 (https=)
IL (1) IL300638A (https=)
WO (1) WO2022038417A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
JP2023550545A (ja) * 2020-11-02 2023-12-01 シムハ・アイエル－１８・インコーポレイテッド インターロイキン－１８バリアントおよび使用の方法
AU2023226512A1 (en) 2022-02-23 2024-08-29 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024102587A2 (en) * 2022-11-11 2024-05-16 Mural Oncology, Inc. Interleukin 18 variants
US20250186594A1 (en) * 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides modified with polymers
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101049A2 (en) * 2001-03-08 2002-12-19 Ares Trading S.A. Interleukin-18 mutants, their production and use
EP2261244A3 (en) * 2003-04-15 2011-02-23 Glaxosmithkline LLC Human il-18 substitution mutants and their conjugates
US20160107999A1 (en) 2013-05-24 2016-04-21 Synaffix B.V. Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
US10266502B2 (en) 2014-01-24 2019-04-23 Synaffix B.V. Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
JP7128121B2 (ja) 2016-06-28 2022-08-30 ヴェンタナ メディカル システムズ， インク． Ｉｈｃ及びｉｓｈアッセイにおけるシグナル増幅のためのクリックケミストリーの応用
IL272635B2 (en) * 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use

Also Published As

Publication number Publication date
WO2022038417A2 (en) 2022-02-24
KR20230052956A (ko) 2023-04-20
CN116368148A (zh) 2023-06-30
US20220056091A1 (en) 2022-02-24
JP2023538422A (ja) 2023-09-07
EP4200323A2 (en) 2023-06-28
WO2022038417A3 (en) 2022-04-21
IL300638A (en) 2023-04-01
CA3189327A1 (en) 2022-02-24
AU2021327861A9 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
AU2021327861A1 (en) Modified il-18 polypeptides and uses thereof
US12521441B2 (en) Modified IL-2 polypeptides and uses thereof
US20230357342A1 (en) Modified il-18 polypeptides
US20190023760A1 (en) Method for preparing interleukin-2 or interleukin-2 analogues
JPWO2019131964A1 (ja) Ｉｌ−２改変体
US20230303649A1 (en) Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20240116997A1 (en) Activatable il-18 polypeptides
JP2016504335A (ja) Ａｐｊ受容体アゴニストおよびその使用
WO2024150175A1 (en) Conditionally activated proteins and methods of use
JP2008506704A (ja) Ｇｍ−ｃｓｆ成分およびポリマーの複合体
CN117616036A (zh) 用于治疗炎性疾病和自身免疫性疾病的修饰的il-2多肽
US20250186594A1 (en) Il-18 polypeptides modified with polymers

Legal Events

Date Code Title Description
SREP Specification republished